Treatment of early Parkinson’s disease

John Christopher Morgan, Kapil D. Sethi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

From the time of the original description of Parkinson’s disease (PD)1 until the 1960s, the pharmacotherapy of PD was not too complex a matter: anticholinergics were the cornerstone of treatment. The introduction of levodopa in the 1960s and the proof of its effectiveness in the treatment of PD2 have resulted in vastly improved quality of life and reduction of disability in PD patients. Today, there are many choices in the initial pharmacological treatment of early PD,3-9 each having its own strengths and weaknesses. The goal of this chapter is to provide a sound rationale for initial pharmacotherapy in early PD, based upon current scientific evidence and personal experience.

Original languageEnglish (US)
Title of host publicationParkinson's Disease, Second Edition
PublisherCRC Press
Pages1029-1041
Number of pages13
ISBN (Electronic)9781439807156
ISBN (Print)9781439807149
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Parkinson Disease
Drug Therapy
Cholinergic Antagonists
Levodopa
Therapeutics
Quality of Life
Pharmacology

ASJC Scopus subject areas

  • Neuroscience(all)
  • Medicine(all)

Cite this

Morgan, J. C., & Sethi, K. D. (2012). Treatment of early Parkinson’s disease. In Parkinson's Disease, Second Edition (pp. 1029-1041). CRC Press. https://doi.org/10.1201/b12948

Treatment of early Parkinson’s disease. / Morgan, John Christopher; Sethi, Kapil D.

Parkinson's Disease, Second Edition. CRC Press, 2012. p. 1029-1041.

Research output: Chapter in Book/Report/Conference proceedingChapter

Morgan, JC & Sethi, KD 2012, Treatment of early Parkinson’s disease. in Parkinson's Disease, Second Edition. CRC Press, pp. 1029-1041. https://doi.org/10.1201/b12948
Morgan JC, Sethi KD. Treatment of early Parkinson’s disease. In Parkinson's Disease, Second Edition. CRC Press. 2012. p. 1029-1041 https://doi.org/10.1201/b12948
Morgan, John Christopher ; Sethi, Kapil D. / Treatment of early Parkinson’s disease. Parkinson's Disease, Second Edition. CRC Press, 2012. pp. 1029-1041
@inbook{383f7c09bd4942c7aedb4ebff2c9e254,
title = "Treatment of early Parkinson’s disease",
abstract = "From the time of the original description of Parkinson’s disease (PD)1 until the 1960s, the pharmacotherapy of PD was not too complex a matter: anticholinergics were the cornerstone of treatment. The introduction of levodopa in the 1960s and the proof of its effectiveness in the treatment of PD2 have resulted in vastly improved quality of life and reduction of disability in PD patients. Today, there are many choices in the initial pharmacological treatment of early PD,3-9 each having its own strengths and weaknesses. The goal of this chapter is to provide a sound rationale for initial pharmacotherapy in early PD, based upon current scientific evidence and personal experience.",
author = "Morgan, {John Christopher} and Sethi, {Kapil D.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1201/b12948",
language = "English (US)",
isbn = "9781439807149",
pages = "1029--1041",
booktitle = "Parkinson's Disease, Second Edition",
publisher = "CRC Press",

}

TY - CHAP

T1 - Treatment of early Parkinson’s disease

AU - Morgan, John Christopher

AU - Sethi, Kapil D.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - From the time of the original description of Parkinson’s disease (PD)1 until the 1960s, the pharmacotherapy of PD was not too complex a matter: anticholinergics were the cornerstone of treatment. The introduction of levodopa in the 1960s and the proof of its effectiveness in the treatment of PD2 have resulted in vastly improved quality of life and reduction of disability in PD patients. Today, there are many choices in the initial pharmacological treatment of early PD,3-9 each having its own strengths and weaknesses. The goal of this chapter is to provide a sound rationale for initial pharmacotherapy in early PD, based upon current scientific evidence and personal experience.

AB - From the time of the original description of Parkinson’s disease (PD)1 until the 1960s, the pharmacotherapy of PD was not too complex a matter: anticholinergics were the cornerstone of treatment. The introduction of levodopa in the 1960s and the proof of its effectiveness in the treatment of PD2 have resulted in vastly improved quality of life and reduction of disability in PD patients. Today, there are many choices in the initial pharmacological treatment of early PD,3-9 each having its own strengths and weaknesses. The goal of this chapter is to provide a sound rationale for initial pharmacotherapy in early PD, based upon current scientific evidence and personal experience.

UR - http://www.scopus.com/inward/record.url?scp=85055808886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055808886&partnerID=8YFLogxK

U2 - 10.1201/b12948

DO - 10.1201/b12948

M3 - Chapter

SN - 9781439807149

SP - 1029

EP - 1041

BT - Parkinson's Disease, Second Edition

PB - CRC Press

ER -